「arm」の検索結果

Think and work like an expert Agroecologist. Use when a task calls for Agroecologist judgment. Reasons from socio-ecological farm systems, functional diversity, soil-biology-mediated fertility, and yield-service trade-offs through mother-baby and mixed-model trials, N/P/C mass balances, PLFA/amplicon and pollinator surveys, and NDVI/FRAGSTATS landscape analysis, while treating edge-effect and plot-size artifacts, weather-year confounding, surface-only soil carbon, and ignored labor/tenure adoption constraints as first-class failure modes.

日本語の概要は準備中です。原文の説明を表示しています。

Think and work like an expert Antimicrobial Resistance Scientist. Use when a task calls for Antimicrobial Resistance Scientist judgment. Reasons from MIC distributions, ECOFFs, and phenotype–genotype concordance through EUCAST/CLSI AST, CARD/RGI and AMRFinderPlus resistomes, GLASS/WHONET/NARMS surveillance, carbapenemase/ESBL/MRSA mechanism panels, and heteroresistance PAP while treating breakpoint mixing, genotype-without-phenotype overclaim, selection-bias surveillance, and CARD version drift as first-class failure modes.

日本語の概要は準備中です。原文の説明を表示しています。

Adversarial verification of research theses — cross-run/cross-thesis contradiction via the entity index, pre-mortem (Klarman/Kahneman: assume the loss already happened, reverse the path), inversion (Munger: invert, always invert), and wrong_if falsifiability review. ≈50-finding cap sorted by severity; content-derived finding IDs; incremental scoping with three backstops; lifecycle hooks at pillar-complete / thesis-complete / pre-reduction.

日本語の概要は準備中です。原文の説明を表示しています。

CDER-track catalyst analysis for medicines: PDUFA target dates, AdCom votes, sNDA/sBLA label expansions, biosimilar interchangeability and 180-day exclusivity, Orange Book state, and CRL remediation timelines — enumerated, verified, and sized per event for any biotech/pharma ticker or watchlist.

日本語の概要は準備中です。原文の説明を表示しています。

Med-adapted earnings preview: consensus estimates, historical surprises, guidance sensitivities, and the FDA-catalyst overlay (PDUFA/AdCom/trial readouts near the print) for biotech/pharma names.

日本語の概要は準備中です。原文の説明を表示しています。

Med peer benchmarking: select actual biotech/pharma peers via the med universe (drug/indication overlap where possible) and compare med-relevant metrics — pipeline depth, catalyst density, cash position, margins, valuation multiples.

日本語の概要は準備中です。原文の説明を表示しています。

Med-sector overview across med.medicines_biotech and med.medical_devices with med trends, catalysts, FDA-decision context, and a cross-sector ripple map (quantified sign/magnitude per name). Use to frame any biotech/pharma/device analysis before diving into a single name.

日本語の概要は準備中です。原文の説明を表示しています。

Institutional-grade equity research skills for AI agents. 80 Claude-type skills across 14 verticals (equity-research-core, models-and-pitches, bio-pharm, scenarios, quantitative-analysis, idea-generation, options-derivatives, business-intelligence, industry-analysis, macro-strategy, portfolio-strategy, technical-analysis, risk-and-psychology, trading-as-business) powered by agentii.ai's agent-use-ready SEC filing data plane — SEC filings and 15K+ earnings call transcripts, 15.99M XBRL facts, and company profiles for 1,146+ US-public-equity tickers. Features the three-layer retrieval protocol (Document Discovery → Page Map → Deep Read, with deep-outline escalation) — measured, not asserted: 97.5% saved against a sequential read, and the page map itself is 10.0% of one (spec 062 T030, 2026-09-23) — server-side parallel multi-period search via search_cross_period, a full Excel/PPT generation pipeline with 3-tier office backend support, and the spec-046 governance layer (constitution, thesis and single-skill modes, mechanical gates, and a template-owned disclaimer on generated reports).

日本語の概要は準備中です。原文の説明を表示しています。

Provider-independent production workflow for AI-assisted fashion campaigns, lookbooks, editorial fashion films, ecommerce/editorial hybrids, social cutdowns, virtual try-on assets, generated model/lifestyle ads, and retouched fashion visuals; use when an agent must plan, prompt, produce, review, localize, or deliver fashion imagery or video while preserving garment truthfulness, model consent, fit representation, claims substantiation, platform compliance, accessibility, and fashion QA.

日本語の概要は準備中です。原文の説明を表示しています。

Production guidance for reusable layered 2D character rigs in browser-rendered and video media. Use for SVG hierarchies, pivots and constraints, FK/IK planning, pose and facial libraries, acting, cycles, deterministic handoff, crop variants, and rig QA; not for character concept continuity, 3D armatures, or motion-capture solving.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes CRISPR drug-modifier (chemogenomic) screens with drugZ (Li & Hart 2019 Genome Med), a bidirectional Z-score method that identifies synthetic-lethal sensitizing genes and resistance-conferring suppressor genes from vehicle vs drug comparisons. Covers vehicle-anchored design (not Day-0), the bidirectional Z math giving 2-3x sensitivity over MAGeCK / STARS / edgeR / RIGER on drug screens, per-gene sumZ and normZ, synth (sensitizer) vs supp (suppressor) FDR, multi-dose handling, integration with control sgRNAs, and comparison with MAGeCK MLE with dose covariate. Use when running a drug-modifier CRISPR screen, identifying sensitizing or resistance genes for a drug candidate, choosing drugZ vs MAGeCK MLE for chemogenomic analysis, troubleshooting low-effect drug screens where MAGeCK lacks sensitivity, or designing a drug-screen layout (vehicle vs drug arms).

日本語の概要は準備中です。原文の説明を表示しています。

Corrects the gene-independent copy-number artifact in CRISPR-Cas9 screens (Aguirre 2016 / Munoz 2016 Cancer Discov) where amplified loci appear essential from DNA-damage burden of simultaneous cuts. Covers the p53-dependent G2-arrest mechanism, CRISPRcleanR (Iorio 2018) unsupervised pre-hoc correction, CERES (Meyers 2017) joint CN + gene-effect model, Chronos (Dempster 2021) DepMap-standard population-dynamics + CN model with lowest residual bias, the decision tree by data availability, the Spearman LFC-vs-CN diagnostic, focal-amplification examples (ERBB2 in HER2+, MYC in colorectal, FGFR1 in head and neck), and CRISPRi/a alternatives that bypass the artifact. Use when screening cancer cell lines, diagnosing essentiality at amplified loci, choosing CRISPRcleanR / CERES / Chronos, deciding whether CN correction is needed before MAGeCK / BAGEL2 / drugZ, or switching from Cas9 to CRISPRi.

日本語の概要は準備中です。原文の説明を表示しています。

Test whether two or more traits share a causal variant at a locus using Bayesian colocalization (coloc.abf, coloc.susie, HyPrColoc, moloc, eCAVIAR, SMR/HEIDI, PWCoCo, SharePro). Use when integrating GWAS with eQTL/sQTL/pQTL/mQTL, distinguishing shared causal variants from LD-driven coincidence, handling allelic heterogeneity, choosing between single-causal vs multi-causal methods, picking PP.H4 thresholds, running sensitivity over p12, or harmonising summary statistics for colocalization.

日本語の概要は準備中です。原文の説明を表示しています。

Project gene annotations across genomes using TOGA (Kirilenko 2023 whole-genome-alignment chain-based projection with intactness classification), CESAR 2.0 (Sharma & Hiller 2017 codon-aware exon projection), LiftOff (Shumate & Salzberg 2020 reference-based annotation transfer), Liftover (UCSC), GeMoMa (Keilwagen 2019 evidence-based projection), and Comparative Annotation Toolkit (CAT). Use when transferring annotations from a well-annotated reference to query genome(s), classifying gene-loss vs gene-intact across many genomes at scale, building Zoonomia-style comparative annotations across hundreds of mammals or birds (Kirilenko 2023), detecting pseudogenization, projecting alternative isoforms, or selecting between WGA-anchored (TOGA) vs ortholog-based (LiftOff) annotation transfer strategies.

日本語の概要は準備中です。原文の説明を表示しています。

Integrate multiple scRNA-seq samples/batches using Harmony, scVI, Seurat anchors, and fastMNN. Remove technical variation while preserving biological differences. Use when integrating multiple scRNA-seq batches or datasets.

日本語の概要は準備中です。原文の説明を表示しています。

Bead-based normalization for CyTOF and high-parameter flow cytometry. Covers EQ bead normalization, signal drift correction, and batch normalization. Use when correcting instrument drift in CyTOF or harmonizing data across batches.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Embedded hardware debugging workflow for probe-rs targets using embedded-debugger-mcp. Use when Codex or Claude Code needs to inspect debug probes, validate embedded debugger setup, start the MCP server, guide a user through ARM Cortex-M/RISC-V flashing/debugging/RTT workflows, or operate without installing an MCP client by using the CLI plus prompts.

日本語の概要は準備中です。原文の説明を表示しています。

Add strategic color to monochromatic or dull interfaces using oklch for perceptually uniform palettes. Generates harmonious color systems with automatic light/dark variants and accessible contrast ratios.

日本語の概要は準備中です。原文の説明を表示しています。

A terminal-native marketing system rendered entirely in Berkeley Mono — every word on the page, from the hero headline down to the footer fine print, is monospaced. The page itself reads like a manpage or a static-site README: warm cream canvas (`#fdfcfc`), nearly-black ink (`#201d1d`), 4px-radius rectangles for the few interactive elements, and bracketed `[+]`/`[-]` ASCII markers used as bullets. The brand's only "visual moment" is a single dark hero card that mocks up the OpenCode TUI itself — black background, monospaced terminal output, ASCII pipe characters, and a wordmark rendered as block-pixel ASCII. Every section sits as a hairline-bordered text block on the cream canvas with no shadows, no gradients, no decorative imagery, and no non-monospaced character anywhere in the system.

日本語の概要は準備中です。原文の説明を表示しています。

Greet the user warmly and demonstrate the minimal shape of a valid Agent Skill.

日本語の概要は準備中です。原文の説明を表示しています。

Use for all frontend and web UI tasks by default to apply a business-agnostic desktop web visual style system with medium-strength guardrails; if an existing design system is present, follow it first and use this skill only as a style harmonizer.

日本語の概要は準備中です。原文の説明を表示しています。

Generate beautiful, distinctive HTML/CSS/JS control panels for MATLAB uihtml components. 8 built-in styles (Clean, Material, Cosmic Dark, Neumorphic Dark, Dashboard Light, Midnight Gradient, Minimal Mono, Warm Dark) plus custom aesthetics. Produces production-grade UI with sliders, buttons, toggles, and panels. Use when building visually polished MATLAB app UIs with uihtml.

日本語の概要は準備中です。原文の説明を表示しています。

Design analytics-driven browser test matrices and execute cross-browser tests. Covers BrowserStack/Sauce Labs configuration, Playwright browser channels, common cross-browser CSS/JS divergences, a known-issues documentation log, and progressive enhancement validation. Use when: "cross-browser," "browser matrix," "BrowserStack," "Safari issues," "browser compatibility," "Edge," "works in Chrome but not Safari." Not for: pixel-level baseline strategy and threshold tuning — use visual-testing; device-farm testing of native/hybrid apps — use mobile-testing. Related: visual-testing, playwright-automation, ci-cd-integration, mobile-testing.

日本語の概要は準備中です。原文の説明を表示しています。